Commercial launch of ZYNTEGLO® (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -
- Chris Krawtschuk appointed chief financial officer -
- Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash -
https://finance.yahoo.com/news/bluebird-bio-reports-third-quarter-120000900.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.